Navigation Links
Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
Date:6/2/2010

SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2010 Global Life Sciences Conference and also at the 9th Annual Needham Healthcare Conference, both in New York.

The live presentation for the Jefferies conference takes place on Wednesday, June 9, 2010 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.  The live presentation for the Needham conference takes place on Thursday, June 10, 2010 at 8:40am Eastern Time / 5:40am Pacific Time.  Both presentations will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
2. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
3. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
4. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
5. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Amends Corporate Headquarters Lease
7. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
8. Neurocrine Biosciences Secures Committed Equity Financing Facility
9. Neurocrine Biosciences Reports Second Quarter 2009 Results
10. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 27, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; ... Friday, February 24, 2017 a total of 10,672,750 common share ... per common share. Proceeds from the exercise of these warrants ... Treasury.   ... "We are grateful for this expression of confidence by our ...
(Date:2/27/2017)... , Feb. 27, 2017 Fluxion Biosciences ... Spain has been appointed as a Certified ... The IsoFlux system will be used in Genetracer Biotech,s ... to lung and colon cancer, with plans to move ... laboratory is utilizing Fluxion,s IsoFlux System to isolate, recover, ...
(Date:2/25/2017)... , ... February 25, 2017 , ... ... Verified Clinical Trials in an ongoing effort to create meaningful change by ... and pharmaceutical research with emphasis on consumers and patients’ mental health well-being. , ...
(Date:2/24/2017)... Feb. 24, 2017 Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... to participate in its previously announced rights offering ... shares of common stock and Series C Convertible ... listed warrants. As previously announced, ...
Breaking Biology Technology:
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm Reports ... the laboratory use of nuclear magnetic resonance spectroscopy ... end-users and profiled current practices, developments, trends and ... well as growth and opportunities. These areas include ... NMR instruments, needs and innovation requirements, hyphenated NMR ...
(Date:1/19/2017)... January 19, 2017 According to a new report published ... 2014 - 2022," the global biometric sensor market is expected to garner $1.5 ... In 2015, Asia-Pacific dominated the global market and contributed ... Continue Reading ... ...
Breaking Biology News(10 mins):